U.S. markets close in 29 minutes

Evaxion Biotech A/S (EVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.61+0.16 (+2.84%)
As of 3:24PM EDT. Market open.
Full screen
Loading interactive chart...
  • Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study
    Benzinga

    Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study

    Evaxion Biotech A/S (NASDAQ: EVAX) has announced results from its Phase 1/2a trial of EVX-01 in metastatic melanoma. Data from the trial showed that EVX-01 in combination with a PD-1 checkpoint inhibitor was safe, with only mild and moderate adverse events observed. Combined therapy with EVX-01 demonstrated an objective response rate of 67% across all nine patients, including 22% Complete Response (CR) and 44% Partial Response (PR). Among the four patients on the highest two doses, there was an

  • Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
    GlobeNewswire

    Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02

    New clinical data demonstrates antitumor effect of EVX-01 in combination with anti-PD1 treatmentObjective Response Rate (ORR) of 67% with EVX-01 + anti-PD1 treatment in nine metastatic melanoma patients, including 22% Complete Response (CR) and 44% Partial Response (PR)Clinical trial data supports the proprietary AI-Immunology platform, PIONEER, with regard to: neoepitope prediction, de novo T-cell activation and clinical response in cancer patients Phase 2 trial of EVX-01 in melanoma, planned t

  • Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8
    GlobeNewswire

    Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8

    COPENHAGEN, Denmark, July 07, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss Phase 1/2a data on EVX-01 and EVX-02 on Thursday, July 8, 2021. Lars Wegner, CEO of Evaxion, Glenn Vraniak, CFO, and Niels Iversen Moller, co-founder and CBO,